Evidence map›Paper›PMID 39630753›Full record

ReviewEinstein (Sao Paulo, Brazil)2024

Overview of the development, characterization, and function of human types 1, 2, and 3 innate lymphoid cells.

Laiz Cameirão Bento, Nydia Strachman Bacal, Luciana Cavalheiro Marti

Abstract readReview
In one paragraph

Review in Einstein (Sao Paulo, Brazil), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. The Dual Role of Natural Killer Cells in the Septic Liver.Journal of inflammation research · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laiz Cameirão BentoClinical Pathology Laboratory, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0003-2258-4150
Nydia Strachman BacalClinical Pathology Laboratory, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0003-0684-6704
Luciana Cavalheiro MartiExperimental Biology Laboratory Prof. Dr Geraldo Antonio de Medeiros Neto, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-3890-0827

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoiesis is characterized by the differentiation and maturation of multipotent stem cells into hematopoietic cells. Common lymphoid progenitor cells differentiate into B and T lymphocytes; natural killer cells can also originate from common lymphoid progenitors. In recent years, a cellular subtype of lymphocytes, called innate lymphocytes, has been described. Innate lymphoid cells (ILCs) play an important effector and regulatory role in innate immunity, and similar to natural killer cells, depend on the γc and Id2 chains for their development. These cells are divided into three main subtypes according to their characteristics, namely type 1 innate lymphocytes (ILC1), type 2 (ILC2), and type 3 (ILC3); the production of cytokines and transcription factors is essential for this classification. Furthermore, these cells have high plasticity, which allows them to change their phenotype in response to the environment. ILCs have recently been characterized further and emerged as a family of effectors and regulators of innate immune responses. Uncontrolled activation of these cells can contribute to inflammatory, autoimmune diseases and cancer. The current review aimed to describe their main characteristics, immunophenotypes, and plasticity, and based on the existing literature, suggested a phenotypic analysis to differentiate innate lymphocytes from natural killer cells, and across the subsets.

Indexed as

Immunity, InnateKiller Cells, NaturalLymphocytesCell DifferentiationCytokinesHumansImmunophenotypingLymphocyte SubsetsCytokines

Identifiers

PMID39630753
PMCPMC11634355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.